Expert Interview
After Genocea's blistering stock move today, is the GEN-003 data enough for the company to shed its micro-cap status?
Ticker(s): GNCAAn immunologist with extensive knowledge of the GEN-003 program as well as treating patients with herpes.
Please describe your background treating patients with Type 2 Herpes.
Added By: joe_mccannCan you give your high level thoughts on the GEN-003 12 month data released March 31st? For reference here is the press release link
How does this data compare in your opinion to oral antiviral treatment?
What % of your patients would you consider prescribing GEN-003 to?
Does this data look like GEN-003 could become the standard of care for Herpes Simplex-2 patients?
How statistically valid would you consider slide 8 in the presentation in this link:
http://bit.ly/1UvQfrx
Does the data disclosed on slides 8 & 9 warrant a Phase 3 study with the current GEN-003 product in your opinion?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
